CannPal Animal Therapeutics Shareholder Increases Stake to Almost 20%

 

CannPal Animal Therapeutics Ltd (ASX:CP1) has had one of its major shareholders, Merchant Funds Management, increase its stake to 19.61% from 18.61%.

The increase was the result of a series of on-market trades, the most recent being the purchase of 1 million shares last Thursday 16 May for $145,478.

Merchant is a boutique Perth-based fund manager focused on early-stage ASX opportunities.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The buying activity from Merchant follows purchases from a number of CannPal board members.

The most recent purchase was from founder and managing director Layton Mills who purchased 65,000 shares via on-market trades earlier this month.

 

 

 

 

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company's lead drug candidate under development targeting pain and inflammation control in dogs.

 

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *